{"id":"W2577615809","doi":"10.1182/blood.v112.11.864.864","title":"Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Lenalidomide; Multiple myeloma; Refractory (planetary science); Proteasome inhibitor; Internal medicine; Thalidomide; Progressive disease; Phases of clinical research; Dexamethasone; Gastroenterology; Oncology; Pharmacology; Toxicity; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003074559,0.001827305,0.001944688,0.0003814631,0.0006107134,0.0008652325,0.0007892471,0.001327077,0.003237163],"category_scores_gemma":[0.001297838,0.0005439921,0.001061124,0.0003928128,0.001037539,0.0008774691,0.000364715,0.00383891,0.0009299602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001038159,"about_ca_system_score_gemma":0.001399135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001160542,"about_ca_topic_score_gemma":0.002897664,"domain_scores_codex":[0.9993142,0.000352496,0.00003506096,0.00009190611,0.00006236888,0.0001439495],"domain_scores_gemma":[0.9986961,0.0003501905,0.0001868504,0.00008319403,0.00008777928,0.0005959543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5300381,0.1174574,0.02534967,0.00119155,0.001554911,0.0009481105,0.001003703,0.005572923,0.13248,0.000435834,0.01118212,0.1727857],"study_design_scores_gemma":[0.3271756,0.603734,0.05163627,0.00004487943,0.0006676791,0.0006928854,0.00009542783,0.001885933,0.009535988,0.0002671492,0.004219806,0.00004438657],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905301,0.001737853,0.0007483179,0.0006447404,0.00005937885,0.002157028,0.001739111,0.0001558765,0.002227604],"genre_scores_gemma":[0.991069,0.0007307316,0.001323857,0.0007765868,0.0001380443,0.001235509,0.003351967,0.00004671514,0.001327752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003237163,"threshold_uncertainty_score":0.01626003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06796061892251935,"score_gpt":0.332436046035458,"score_spread":0.2644754271129386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}